---
title: "Biogen Inc. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293074237.md"
description: "Biogen Inc. (BIIB) shares fell 1.40% to $205.99 on Friday, underperforming competitors like Johnson & Johnson and AbbVie during a broader market decline. The drop ended a two-day winning streak, with Biogen closing 6.25% below its 52-week high. Trading volume was below the 50-day average."
datetime: "2026-07-17T20:57:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293074237.md)
  - [en](https://longbridge.com/en/news/293074237.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293074237.md)
generator: "portal-rs"
---

# Biogen Inc. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Biogen Inc. (BIIB) slid 1.40% to $205.99 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index falling 1.01% to 7,457.69 and Dow Jones Industrial Average falling 0.77% to 52,146.42.

The stock's fall snapped a two-day winning streak.

Biogen Inc. closed 6.25% below its 52-week high of $219.72, which the company achieved on June 29th.

The stock underperformed when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.23% to $253.04, Pfizer Inc. (PFE) fell 0.36% to $25.05, and AbbVie Inc. (ABBV) rose 0.04% to $254.49.

Trading volume (1.2 M) remained 143,288 below its 50-day average volume of 1.3 M.

Data source: Dow Jones Market Data, FactSet. Data compiled July 17, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

07-17-26 1657ET

### Related Stocks

- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Amundi Purchases 726,004 Shares of Biogen Inc. $BIIB](https://longbridge.com/en/news/298275504.md)
- [Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing](https://longbridge.com/en/news/298400767.md)
- [Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease](https://longbridge.com/en/news/297867394.md)
- [Apnimed, Inc. reports Q2 results](https://longbridge.com/en/news/298366495.md)
- [Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI(R) (lecanemab) for Early Alzheimer's Disease](https://longbridge.com/en/news/298340520.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**